Search Technologies

The National Institute on Drug Abuse’s Medicinal Chemistry Section seeks partners interested in collaborative research to co-develop analogues of modafinil for the treatment of drug abuse and sleep and attention disorders.

The National Cancer Institute's Laboratory of Pathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a method for target-activated microdissection.

The National Cancer Institute seeks parties interested licensing or collaborative research to co-develop thalidomide analogs to treat cancer and inflammatory diseases.

Researchers at the National Cancer Institute have discovered small molecule inhibitors of Chk2 for the treatment of cancer.

Scientists at NIH have identified 7 new agonist epitopes of the MUC-1 tumor associated antigen. Compared to their native epitope counterparts, peptides reflecting these agonist epitopes have been shown to enhance the generation of human tumor cells, which in turn have a greater ability to kill human tumor cells endogenously expressing the native MUC-1 epitope.

The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to co-develop antibody-based therapeutic against MERS-CoV, including animal studies, cGMP manufacturing, and clinical trials.

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for gene therapy for CRX retinopathies such as Leber congenital amaurosis, retinitis pigmentosa, and cone-rod dystrophy.

The National Cancer Institute, Nanobiology Program seeks parties to co-develop cancer therapeutics base on antibody fragments.

The National Cancer Institute (NCI) seeks non-exclusive licensees for an ovarian cancer cell line, A2780, and its cisplatin- and/or adriamycin-resistant derivatives, A2780CIS and A2780ADR. These cell lines are excellent research tools to study ovarian cancer with a focus on drug resistance.